Andres Y. Maldonado, an analyst from H.C. Wainwright, reiterated the Buy rating on Protara Therapeutics. The associated price target is $23.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andres Y. Maldonado has given his Buy rating due to a combination of factors reflecting Protara Therapeutics’ promising advancements in their clinical programs. The company’s progress in its lead programs, particularly the fully enrolled Phase 2 ADVANCED-2 trial for NMIBC, highlights its potential to address unmet medical needs with TARA-002, especially for patients with no FDA-approved alternatives. The anticipated interim analysis in early 2026 could provide significant insights into the therapy’s efficacy.
Moreover, Protara’s ongoing Phase 2 STARBORN-1 trial for pediatric lymphatic malformations and the upcoming THRIVE-3 trial for IV Choline Chloride demonstrate the company’s strategic focus on rare diseases and conditions with high unmet needs. The potential for regulatory advantages, such as Priority Review Voucher eligibility, and the substantial market opportunities in NMIBC, pediatric LM, and IV Choline Chloride further support the Buy rating. These factors, combined with the company’s strong execution and favorable safety profiles, underpin Maldonado’s positive outlook on Protara Therapeutics.
Y. Maldonado covers the Healthcare sector, focusing on stocks such as I-MAB, Merus, and Scholar Rock Holding. According to TipRanks, Y. Maldonado has an average return of 1.6% and a 37.01% success rate on recommended stocks.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $22.00 price target.